S tress-related mucosal disease and subsequent upper gastrointestinal (UGI) bleeding were associated with significantly increased morbidity and mortality among patients admitted to the intensive care unit (ICU) (1, 2) . Whereas the overall incidence of clinically significant UGI bleeding is approximately 4%, overt bleeding attributable to stress-related mucosal disease may occur in up to 25% of critically ill patients who do not receive stress ulcer prophylactic therapy (1, (3) (4) (5) . The mortality rate among the patients with stress-related clinically important bleeding was 48.5%, which is significantly higher than 9.1% for those without such bleeding (6) . Two significant risk factors associated with clinically important stress-related mucosal disease bleeding among critically ill patients were mechanical ventilation for Ͼ48 hrs and the presence of coagulopathy (6) .
Several agents such as antacids, sucralfate, and histamine-2 receptor antagonists (H2RAs) have been used for stressrelated UGI bleeding prophylaxis among patients admitted to ICU. Guidelines by American Society of Health-System Pharmacists and Surviving Sepsis Campaign suggested that patients at higher risk should receive stress ulcer prophylaxis, and the medication mostly suggested was H2RA, even though the definitive recommendation about choice among H2RAs and all other agents cannot be made based on available evidence (7, 8) .
Proton pump inhibitors (PPIs) were launched in the late 1980s and became widely used because of their promising Objective: To examine the efficacy and safety of proton pump inhibitors in comparison with histamine-2 receptor antagonists for stress-related upper gastrointestinal bleeding prophylaxis among critical care patients.
Data Sources: PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov.
Study Selection: Randomized, controlled trials that directly compare proton pump inhibitors with histamine-2 receptor antagonists in prevention of stress-related upper gastrointestinal bleeding in intensive care unit patients published before May 30,
2008.
Data Extraction: Two reviewers independently applied selection criteria, performed quality assessment, and extracted data. The primary outcome was the incidence of stress-related upper gastrointestinal bleeding, and the secondary outcome measures were the incidence of pneumonia and intensive care unit mortality.
Data Synthesis: The random effect model was used to estimate the pooled risk difference between two treatment arms irrespective of drug, dosage, and route of administration.
Results: We identified seven randomized, controlled trials with a total of 936 patients for planned comparison. The overall pooled risk difference (95% confidence interval; p value; I 2 statistics) of stress-related upper gastrointestinal bleeding comparing proton pump inhibitors vs. histamine-2 receptor antagonists was ؊0.04 (95% confidence interval, ؊0.09 -0.01; p ‫؍‬ .08; I 2 ‫؍‬ 66%). In the sensitivity analysis, removing the Levy study significantly reduced the heterogeneity (from I 2 ‫؍‬ 66% to I 2 ‫؍‬ 26%) and shifted the overall risk difference closer to the null (pooled risk difference, ؊0.02; 95% confidence interval, ؊0.05-0.01; p ‫؍‬ .19). There was no difference between proton pump inhibitors and histamine-2 receptor antagonists therapy in the risk of pneumonia and intensive care unit mortality, with pooled risk differences of 0.00 (95% confidence interval, ؊0.04 -0.05; p ‫؍‬ .86; I 2 ‫؍‬ 0%) and 0.02 (95% confidence interval, ؊0.04 -0.08; p ‫؍‬ .50; I 2 ‫؍‬ 0%), respectively.
Conclusions: This meta-analysis did not find strong evidence that proton pump inhibitors were different from histamine-2 receptor antagonists in terms of stress-related upper gastrointestinal bleeding prophylaxis, pneumonia, and mortality among patients admitted to intensive care units. Because of limited trial data, future well-designed and powerful randomized, clinical trials are warranted. (Crit Care Med 2010; 38:1197-1205) KEY WORDS: proton pump inhibitors; histamine H2 antagonists; gastrointestinal hemorrhage; critical care; pneumonia; metaanalysis effect on acid suppression and flexibility in administering different formulations; they were advocated to be used for stressrelated UGI bleeding prevention among critically ill patients (9, 10) . Two national surveys of physician management decisions on the stress ulcer prophylaxis have shown that PPIs were chosen as the initial treatment by 3% of the survey respondents in 1998, and that number substantially increased to 23% in the survey conducted in 2002; in contrast, H2RAs use noticeably declined from 77% to 64% (11, 12) . Whereas several small, openlabel trials documented the superiority of PPIs in maintaining intragastric pH Ͼ4 (13) (14) (15) (16) , results from randomized comparisons between PPIs and H2RAs on stress-related UGI bleeding prophylaxis among patients admitted to ICU were inconsistent. Furthermore, recent studies also observed an increased risk of pneumonia associated with use of acidsuppression agents, especially PPIs (17, 18) . In this study, we conducted a metaanalysis to combine efficacy and safety information from all published trials to obtain pooled risk difference of PPIs vs. H2RAs in UGI bleeding prophylaxis and the incidence of pneumonia associated with these treatment regimens.
MATERIALS AND METHODS

Literature Search Strategy
We searched PubMed, EMBASE, Cochrane Library (which includes the Cochrane Database of Systematic Reviews; the Database of Abstracts of Reviews of Effects; and the Cochrane Register of Controlled Trials), and the ClinicalTrials.gov web site for relevant articles. All databases were searched from the beginning until May 2008. The search strategy was repeatedly performed every week until October 2009 for new published articles, but no other studies that met the inclusion criteria were identified. Medical subjects heading terms used for key word and text word searching included stress ulcers, gastrointestinal hemorrhage, gastrointestinal bleeding, stressrelated mucosal diseases, stress-related mucosal damages, pneumonia, critically illness, critical care, intensive care unit, proton pump inhibitors, omeprazole, lansoprazole, esomeprazole, pantoprazole, and rabeprazole. The references of six review articles (19 -24) on the prevention of stress ulcer among critical care patients were examined to identify additional articles that were not found in the computerized databases. Additional reports were identified from reference lists of the identified articles.
Selection Criteria for Studies
We included randomized and quasi-randomized trials involving adults patients admitted to medical or surgical ICUs for UGI bleeding prophylaxis. Included studies directly compared any PPIs vs. any H2RAs, regardless of drug, dosage, and route of administration. Only English articles published before May 30, 2008 were included. Studies were excluded if placebo, antacids, or sucralfate rather than H2RAs were used as the comparison group. The definition of stress-related UGI bleeding and pneumonia adopted by the individual research were not assumed to be inclusion or exclusion criteria. We excluded pharmacokinetic studies, studies that used intragastric pH as the only outcome of interest, and studies that did not clearly present whether patients were admitted to ICU.
Efficacy and Safety Outcomes
The efficacy outcome measure was the incidence of stress-related UGI bleeding (proportion of intention-to-treat population with UGI bleeding of any definition). The safety outcome measures were the pooled incidence of pneumonia and ICU mortality.
Data Extraction and Quality Assessment
Two reviewers (PCL and CHC) independently evaluated each identified study and abstracted relevant characteristics, including quality of the studies. Disagreement on specific studies between the two reviewers was resolved through discussion. Abstracted information included study characteristics (author, published year), patient characteristics (setting, mean age, proportion of patients who were male, number of risk factors for stress ulcer), regimen (drug, dosage, frequency, and administered route), number of intention-totreat and per-protocol populations, drop-out rate, enteral nutrition, efficacy, and safety outcomes. The authors of the included studies were contacted for the unpublished data. The quality of each study was assessed by Jadad criteria and the score Ͻ3 meant poor study quality (25) .
Statistical Analysis
We analyzed the result with (27) were used to estimate the pooled risk differences and 95% confidence intervals (CI) of the efficacy and safety outcomes between PPI and H2RA arms from eligible studies. The Mantel-Haenszel method was used for within-study variance and the DerSimonian and Laird method was used for incorporating both within-study and betweenstudy variances. Heterogeneity was assessed using Cochran's Q statistic and quantified using the I 2 statistic (28). I 2 statistic represents the percentage of total variation attributable to between-study heterogeneity rather than sampling error. I 2 values of approximately 25%, 50%, and 75% are considered as representing low, moderate, and high heterogeneity, respectively (29) . To further explore the potential source of heterogeneity, we performed a sensitivity analysis and subgroup analysis. A sensitivity analysis was performed by removing one study at a time. The subgroup analyses took into account the following variables of the included studies: probability of ventilation need of Ͼ48 hrs as an entry criterion, presence of balanced patient characteristics at baseline, and year of publication (before or after 2000). A formal test of interaction was performed for each of all subgroups to examine if the difference in effect size between two subgroups was statistically significant. Results for interactions were considered as statistically significant for p Ͻ .05. We assessed the presence of publication bias by examining funnel plots (risk difference vs. the standard error of risk difference) for asymmetry.
RESULTS
Study Identification
We identified 1213 studies published in the English language that were potentially relevant to stress-related UGI bleeding prophylaxis among ICU patients from computerized literature databases, reference lists of systematic reviews, and identified articles ( Fig. 1 ). After independent review by two reviewers, a total of 1164 irrelevant studies and 18 duplicate reports were excluded. We also excluded another 24 because of one of the following reasons: enrolling non-ICU patients; nonrandomized studies; placebo or sucralfate as the comparison group; no available UGI bleeding outcome; and only pediatric patients were included and they overlapped patient population with other studies. A total of seven randomized trials comparing PPIs with H2RAs for stressrelated UGI bleeding prophylaxis among ICU patients were included in the metaanalysis for planned comparison (30 -36) . These seven studies, five (30, 31, 34 -36) in peer-reviewed journals and two (32, 33) in abstract form, were published from 1993 through 2008, with number of study subjects ranging from 41 to 359, included a total of 936 patients.
Characteristics of the seven included studies are summarized in Table 1 trial, 143 patients). Drop-out rate and enteral nutrition were reported in four and three trials, respectively, with rates ranging from 8.6% to 19.3% for drop-out rate, and almost nothing by mouth for 42% in enteral nutrition. The definition of stressrelated UGI bleeding was described in five trials. For safety outcomes, six trials evaluated the incidence of pneumonia, among which four studies reported the definition of pneumonia as new or progressed infiltrate on chest radiography, as well as positive laboratory or physical examination finding (e.g., fever, hypothermia, leucocy-tosis, blood and/or sputum culture, or purulent tracheal aspirate or sputum) ( Table 2) .
Study Quality
The quality of the included studies was assessed by Jadad criteria (see Supplemental Digital Content 1, http://links.lww.com/CCM/A119). The Jadad scores of the included studies ranged from 1 to 5. All studies published after 2000 had good study quality. Five trials reported balanced patient characteristics at baseline between two treatment groups after randomization. Levy et al (31) observed that the mean number of risk factors was significantly higher for patients in the H2RA group than those in the PPI group in their study.
UGI Bleeding
The observed risk difference for UGI bleeding comparing PPIs vs. H2RAs in these studies ranged from Ϫ0.25 to 0.00, with a pooled risk difference of Ϫ0.04 (95% confidence interval [CI], Ϫ0.09 - 0.01; p ϭ .08) based on a random effect model (Fig. 2 ). There was a significant heterogeneity among seven included studies with regard to the risk difference of stress-related UGI bleeding (p ϭ .008; I 2 ϭ 66%). The sensitivity analysis of removing one study at a time did not have a large effect on the magnitude of the overall results of stress-related UGI bleeding (pooled risk difference range, Ϫ0.06-Ϫ0.02). Removing the Levy study significantly reduced the heterogeneity (from I 2 ϭ 66% to I 2 ϭ 26%) and shifted the overall risk difference closer to the null (pooled risk difference, Ϫ0.02; 95% CI, Ϫ0.05-0.01; p ϭ .19) (see Supplemental Digital Content 2, available at http://links.lww.com/CCM/A120). We also examined the stress-related UGI bleeding by using odds ratios and risk ratios as outcome measures. There was also no substantial difference between PPI and H2RA treatment ( Table 3) .
In subgroup analyses, there was no difference between PPI and H2RA treatment in the trials that reported balanced patient characteristics at baseline (pooled risk difference, Ϫ0.01; 95% CI, Ϫ0.04 -0.01; p ϭ .34; I 2 ϭ 0%) and the trials that needed the risk factor of mechanical ventilator Ն48 hrs as an entry criterion (pooled risk difference, Ϫ0.02; 95% CI, Ϫ0.05-0.01; p ϭ .24; I 2 ϭ 10%), but the heterogeneity was reduced ( Figs. 3 and 4) . The results were also not different between PPI and H2RAs treat-ment no matter whether enteral or intravenous PPI was chosen. (Fig. 5 ). There was no difference in stress-related GI bleeding between subgroup with regard to types of PPI (omeprazole or pantoprazole), administration route of H2RA (continuous vs. intermittent intravenous infusion), study quality (Jadad score Ն 3 vs. Ͻ 3), the definition of UGI bleeding (good or poor), the number of risk factors (with Ն2 risk factors vs. those with Ն1 risk factor), and the dose of PPI (Ͼ40 mg vs. Յ40 mg). Only the studies published before 2000 had a favorable outcome with PPIs (pooled risk difference, Ϫ0.11; 95% CI, Ϫ0.21-Ϫ0.01; p ϭ .03; I 2 ϭ 54%) (see Supplemental Digital Content 3-9, available at http://links.lww.com/CCM/A121; http://links.lww.com/CCM/A122; http://links.lww.com/CCM/A123; http://links.lww.com/CCM/A124; http://links.lww.com/CCM/A125; http://links.lww.com/CCM/A126; and http://links.lww.com/CCM/A127). A formal test for the difference of pooled risk differences between subgroups was conducted (using p for heterogeneity). We found significant interactions from two variables: the presence of balanced baseline patient characteristics and the year of publication (Table 4 ).
Publication Bias
The funnel plot revealed an apparent asymmetry that suggested the presence of a potential publication bias, a language bias, inflated estimates by a flawed methodologic design in smaller studies, and/or a lack of publication of small trials with opposite results (Fig. 6 ).
Incidence of Pneumonia
Six studies were included for safety information (31) (32) (33) (34) (35) (36) . There was a substantial variability in the reported risks of pneumonia among individual treatment arms, ranging from 3% to 18%. We found no significant difference in the risk of pneumonia between PPI and H2RA therapy. The pooled risk difference of pneumonia comparing PPI vs. H2RA in six included studies was 0.00 (95% CI, Ϫ0.04 -0.05; p ϭ .86; I 2 ϭ 0%) (Fig. 7A ).
ICU Mortality
ICU mortality rate was reported only in three trials and ranged from 11.6% to 34.0%. The pooled risk difference of ICU mortality comparing PPI vs. H2RA was 0.02 (95% CI, Ϫ0.04 -0.08; p ϭ .50; I 2 ϭ 0%) ( Fig. 7B ).
DISCUSSION
We conducted a systematic review and meta-analysis of randomized, controlled trials directly comparing PPIs and H2RAs with regarding to the effect of stressrelated UGI bleeding prophylaxis, risk of pneumonia, and ICU mortality among ICU patients. We found no strong evidence that PPIs were significantly different from H2RAs in terms of overt or clinically important UGI bleeding prevention, pneumonia, and mortality. These findings, in accordance with the results from previous systematic review and two recently published randomized, controlled trials, suggested that the prophylaxis usage of PPIs or H2RAs reached a similar frequency of UGI bleeding among critically ill patients (20, 33, 36) .
In this study, we found PPIs and H2RAs were associated with similar fre- quency of stress-related UGI bleeding despite PPIs being superior in elevating and maintaining intragastric pH (32, 35) . Possible explanations were that 40% of patients included in our meta-analysis were at low risk for stress-related UGI bleeding. The PPI therapy was not associated with an additional absolute risk reduction, probably because of a relatively low incidence of overt or clinically important bleeding among those patients already receiving H2RA treatment. Furthermore, subgroup analyses revealed that neither intravenous PPI (30, (33) (34) (35) (36) nor higher doses of PPI (30, 33) , even though could reach higher intragastric pH, showed a significant difference in the prevention of stress-related UGI bleeding compared to H2RAs. Previous studies examining intragastric pH change suggested that higher dosage of PPI seemed not to be associated with a further reduced incidence of stress-related UGI bleeding because a target pH Ͼ4 may be required for prevention of stress related mucosal bleeding, whereas target pH Ͼ6 is necessary for prevention of peptic ulcer recurrence (16, 37, 38) . The safety consideration of acidsuppressive therapies among critical care patients has constantly been an important issue. Several studies suggested that acid-suppressive therapy can increase intragastric pH that may cause bacterial gastric colonization and overgrowth, which may lead to increased risk of pneumonia (39, 40) . Meta-analyses conducted by Tryba et al (41) and Cook et al (42) suggested that sucralfate may be associated with lower rates of nosocomial pneumonia and mortality as compared with H2RAs or antacid; the same result was concluded by Prod'hom et al (43) . Nevertheless, the outcome of a randomized, controlled trial with a sample of 1200 enrolled patients revealed that there was no significant difference in the rate of ventilator-associated pneumonia developing between ranitidine and sucralfate treatment (3) . However, the result of a recent cohort study with a sample of 63,878 non-ICU patients demonstrated that PPI use contributed a statistically high risk to hospital-acquired pneumonia (18) . In this meta-analysis with a total of 905 and 569 patients included for pneumonia and mortality comparisons, PPI was not associated with an increased risk of pneumonia or ICU mortality as compared with H2RA, but the pooled estimates had a trend favoring H2RA, opposite to the result of the stress-related GI bleeding prophylaxis effect. There are two major reasons for choosing risk difference instead of relative risk or odds ratio as the outcome measure (44 -46) . First, the estimated risk difference is an absolute risk reduction that can capture explicitly clinical meanings, because it can incorporate the baseline risk and the magnitude of the risk reduction. Second, it also can be calculated even when there was no event in the treatment groups (zero events observed in five arms in three included studies). Even though we also examined the effect of stress-related GI bleeding prophylaxis by using odds ratio and risk ratio in the trials with homogeneity (removed Levy study in our sensitivity analysis), there was no substantial difference between PPI and H2RA treatment.
We have conducted both sensitivity analyses and subgroup analyses to explore the between-study heterogeneity. As a result, we identified that Levy's study and two independent factors may contribute to the observed significant heterogeneity. One of the factors is balanced patient characteristics across patient populations at baseline and the other is the year of publication. In sensitivity analyses, removing Levy's trial decreased the heterogeneity. The risk factors for bleeding were not balanced between groups in Levy's study. The mean number of risk factors was significantly higher for patients in the H2RA group than those in the PPI group (2.7 vs. 1.9) (31), and the stress-related clinically significant bleeding occurred at a higher rate (31%) in those patients receiving ranitidine as compared to omeprazole (6%). This rate was also higher than the reported rate from other studies (range, 0% to 16.0%) (32) (33) (34) (35) . Furthermore, the mortality rate (34%) was higher in Levy's study compared to the rate in the other studies conducted after 2000 (11.6% to 15.2%) (34 -35) , even though the number of risk factors were at least two and four in 66% to 72% and 65% to 69% patients in these two studies. The study by Levy was responsible for subgroup analyses indicating that older studies and studies with lack of risk factors balanced at baseline suggested benefit of PPIs in comparison to newer studies without risk factor imbalance at baseline.
Based on current data, there seemed to be no substantial difference in the frequency of UGI bleeding and pneumonia among oral and intravenous PPIs and intravenous H2RAs. If the decision is made to suppress gastric acid secretion, then patients should be treated based on their individual risk for stress ulcer bleeding (47) . We suggest that health professionals should make treatment decision that also account for convenience of drug administration, potential drug-drug interaction, and cost (48 -50) . Further studies should emphasize patient risk stratification and explore the optimal regimen of stress ulcer bleeding prevention in terms of drug, dosage, mode of administration, timing, and duration among patients with different risk levels. Several limitations in this metaanalysis should be considered. First, despite extensive search of the PubMed, EMBASE, Cochrane Library databases, and ClinicalTrials.gov, as well as reference lists of the identified articles and systematic reviews, we might not have included all published articles because we limited study enrollment to English literature only. Asymmetry of the funnel plots also raised the possibility of publication or language bias. However, our finding of no significant difference between PPI and H2RA was unlikely to be changed unless there were several unpublished, good-quality, large, randomized trials consistently demonstrating considerable effects in favor of PPIs. Second, limited data form included studies may be insufficient to get a precise estimate of summary incidence of adverse event because of small sample size. Third, most of the reports that met our selection criteria were omeprazole trials. More studies are needed to explore the role of different PPIs in stress ulcer prophylaxis.
CONCLUSIONS
This meta-analysis did not find evidence that PPIs were different from H2RAs in terms of stress-related UGI bleeding prophylaxis, pneumonia, and mortality among patients admitted to ICUs. Because of limited trial data, the evidence from our meta-analysis remains inconclusive, and future well-designed, powerful, randomized, clinical trials are warranted.
